# Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2

> **NCT04987554** · NA · UNKNOWN · sponsor: **University of Valladolid** · enrollment: 120 (estimated)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DIETARY_SUPPLEMENT:** glycophosphopeptical AM3
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04987554
- **Lead sponsor:** University of Valladolid
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987554, "Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04987554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*